RxDoctor Payments Data

Rebecca Harris

Nurse Practitioner · Wiggins, MSNPI 1235553462

Payments from drug & device makers

$1,810in general payments, 2019–2025

Across 110 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$774
  • AstraZeneca$218
  • Takeda Pharmaceuticals U.S.A., Inc.$208
  • Johnson & Johnson$133
  • Lilly USA, LLC$125
  • Amgen$53
  • plus $298 from 12 others

What the payments were for

  • Food & beverage$1,810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,810 in reported general payments places this provider in the 80th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$37,156
Medicare patients
160
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide107$119,526
JardianceEmpagliflozin55$53,599
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$28,880
LinzessLinaclotide30$23,227
OzempicSemaglutide20$18,295
VraylarCariprazine Hcl12$16,586
EliquisApixaban19$15,436
Breo ElliptaFluticasone/Vilanterol30$12,226
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,148
RybelsusSemaglutide13$11,808
XareltoRivaroxaban11$11,647
SymbicortBudesonide/Formoterol Fumarate42$10,996
Spiriva HandihalerTiotropium Bromide11$7,455
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$7,328
Combivent RespimatIpratropium/Albuterol Sulfate14$7,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$125$119,526107 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$23$46,74784 claims
AbbVieLinzess, Vraylar, Savella$774$44,89753 claims
Novo NordiskOzempic, Rybelsus$34$30,10333 claims
AstraZenecaBreztri Aerosphere, Symbicort$218$23,14462 claims
PfizerEliquis$13$15,43619 claims
Johnson & JohnsonXarelto$133$11,64711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Wiggins

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →